torsemide has been researched along with azosemide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Cheng, XW; Harada, K; Hirashiki, A; Isobe, S; Izawa, H; Kobayashi, M; Murase, Y; Murohara, T; Nagata, K; Nishizawa, T; Noda, A; Yokota, M | 1 |
| Gramer, M; Hampel, P; Löscher, W; Römermann, K | 1 |
| Gailus, B; Gericke, B; Hampel, P; Johne, M; Kaczmarek, E; Löscher, W; Römermann, K | 1 |
| Gramer, M; Kirchhoff, L; Löscher, W; Schmidt, R; Welzel, B | 1 |
1 trial(s) available for torsemide and azosemide
| Article | Year |
|---|---|
Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide.
Topics: Administration, Oral; Aldosterone; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Norepinephrine; Sodium Potassium Chloride Symporter Inhibitors; Sulfanilamides; Sulfonamides; Sympathetic Nervous System; Systole; Torsemide; Ventricular Dysfunction, Left | 2009 |
4 other study(ies) available for torsemide and azosemide
| Article | Year |
|---|---|
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
Topics: Animals; Brain; Bumetanide; Endothelial Cells; Humans; Mice; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Sulfanilamides; Torsemide | 2021 |
Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Topics: Animals; Anticonvulsants; Bumetanide; Drug Therapy, Combination; Epilepsy; Female; Mice; Phenobarbital; Pilocarpine; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Sulfanilamides; Torsemide; Treatment Outcome | 2021 |
The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Topics: Animals; Asphyxia; Bumetanide; Diuretics; Epilepsy; Furosemide; Rats; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Torsemide | 2023 |